CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy […]
Autor: Firma CatalYm
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1 Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell […]